VAXELIS 0.5 ml susp inj 53 µg 1 pce

7680669400040 CH-66940 J07CA09 08.08.

Active substances:

Toxoidum diphtheriae Toxoidum pertussis Toxoidum tetani

Reimbursement limitations:

BLUTPRODUKTE

Calcul des prix des préparations sanguines sur la base du prix « ex factory », …

No images available

Details

Product number
6694001
CPT
-
Packaging group
1
Unit
Fertigspritze(n)
Composition
polysaccharida haemophili influenzae typus B conjugata cum proteino neisseriae meningitidis B 53 µg corresp. polysaccharida haemophili influenzae typus B 3 µg et neisseria meningitidis B outer membrane protein complex 50 µg, hepatitidis B viri antigenum ADNr 10 µg, toxoidum pertussis 20 µg, haemagglutininum filamentosum 20 µg, pertactinum 3 µg, fimbriae Typ 2 und 3 5 µg, toxoidum diphtheriae min. 20 U.I., toxoidum tetani min. 40 U.I., virus poliomyelitis typus 1 inactivatus (Mahoney) 29 U., virus poliomyelitis typus 2 inactivatus (MEF-1) 7 U., virus poliomyelitis typus 3 inactivatus (Saukett) 26 U., aluminium ut aluminii phosphas et aluminii hydroxyphosphas sulfas amorphus, natrii phosphates, acidum hydrochloridum q.s. ad pH, natrii hydroxidum q.s. ad pH, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.95 mg, residui: glutaralum, formaldehydum, neomycinum, streptomycinum, polymyxinum B, albuminum seri bovis, aluminii thiocyanas, faecis proteina.

Articles (1)

Vaxelis 0.5 ml, Injektionssuspension
Injektionssuspension
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
30/07/2026
Professional SmPC
Français
30/07/2026
Professional SmPC
Italien
30/07/2026

Detailed composition

Substance Quantity Type Category
polysaccharida haemophili influenzae typus B conjugata cum proteino neisseriae meningitidis B
53.0 UG Substance Wirkstoff (Principe actif)
polysaccharida haemophili influenzae typus B
3.0 UG Substance WIIS
neisseria meningitidis B outer membrane protein complex
50.0 UG Substance WIIS
hepatitidis B viri antigenum ADNr
10.0 UG Substance Wirkstoff (Principe actif)
toxoidum pertussis
20.0 UG Substance Wirkstoff (Principe actif)
haemagglutininum filamentosum
20.0 UG Substance Wirkstoff (Principe actif)
pertactinum
3.0 UG Substance Wirkstoff (Principe actif)
fimbriae
5.0 UG Substance Wirkstoff (Principe actif)
toxoidum diphtheriae
- Substance Wirkstoff (Principe actif)
toxoidum tetani
- Substance Wirkstoff (Principe actif)
virus poliomyelitis typus 1 inactivatus
29.0 U Substance Wirkstoff (Principe actif)
virus poliomyelitis typus 2 inactivatus
7.0 U Substance Wirkstoff (Principe actif)
virus poliomyelitis typus 3 inactivatus
26.0 U Substance Wirkstoff (Principe actif)
aluminium
- Substance HIMDK
aluminii phosphas
- Substance HNIDK
aluminii hydroxyphosphas sulfas amorphus
- Substance HNIDK
natrii phosphates
- Substance HNIDK
acidum hydrochloridum
- Substance HNIDK
natrii hydroxidum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.95 MG Substance HBESI
glutaralum
- Substance RESI
formaldehydum
- Substance RESI
neomycinum
- Substance RESI
streptomycinum
- Substance RESI
polymyxinum B
- Substance RESI
albuminum seri bovis
- Substance RESI
aluminii thiocyanas
- Substance RESI
faecis proteina
- Substance RESI

Reimbursement information

Public price
CHF 69.25
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/10/2019

Authorization holder

Future Health Pharma GmbH

8620 Wetzikon ZH

Authorization information

Swissmedic authorization number
66940
Drug name
Vaxelis, Injektionssuspension
Galenic form
SUPA
ATC Code
J07CA09
Authorization status
Z
Dispensation category
B
First authorization
28/08/2019
Authorization expiration date
31/12/9999
IT number
08.08.
Domain
Human medicine
Field of application
Grundimmunisierung und Auffrischimpfung bei Säuglingen und Kleinkindern ab einem Alter von 6 Wochen bis 4 Jahre (vor dem 5. Geburtstag) gegen Diphtherie, Tetanus, Pertussis, Hepatitis B, Poliomyelitis und durch Haemophilus influenzae Typ b (Hib) verursachte invasive Krankheiten.

Packaging details

Description (FR)
VAXELIS 0.5 ml susp inj 53 µg 1 pce
Description (DE)
VAXELIS 0.5 ml Inj Susp 53 µg 1 Stk
Market launch
30/03/2026
Narcotic (BTM)
No

Other packaging sizes

VAXELIS susp inj av 2 aiguilles ser pré 0.5 ml
1 FESP
GTIN: 7680669400019
View
VAXELIS susp inj av 2 aiguilles 10 ser pré 0.5 ml
10 FESP
GTIN: 7680669400026
View
VAXELIS susp inj avec 1 aiguille 10 ser pré 0.5 ml
10 FESP
GTIN: 7680669400033
View
Buy us a coffee Explore the data